Skip to main content
SpringerLink
Log in

Development and Validation of a Discriminating In Vitro Dissolution Method for a Poorly Soluble Drug, Olmesartan Medoxomil: Comparison Between Commercial Tablets

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

A dissolution test for tablets containing 40 mg of olmesartan medoxomil (OLM) was developed and validated using both LC-UV and UV methods. After evaluation of the sink condition, dissolution medium, and stability of the drug, the method was validated using USP apparatus 2, 50 rpm rotation speed, and 900 ml of deaerated H2O + 0.5% sodium lauryl sulfate (w/v) at pH 6.8 (adjusted with 18% phosphoric acid) as the dissolution medium. The model-independent method using difference factor (f 1) and similarity factor (f 2), model-dependent method, and dissolution efficiency were employed to compare dissolution profiles. The kinetic parameters of drug release were also investigated. The obtained results provided adequate dissolution profiles. The developed dissolution test was validated according to international guidelines. Since there is no monograph for this drug in tablets, the dissolution method presented here can be used as a quality control test for OLM in this dosage form, especially in a batch to batch evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ansari M, Kazemipour M, Talebnia J. The development and validation of a dissolution method for clomipramine solid dosage forms. Dissol Technol. 2004;11:16–24.

    CAS  Google Scholar 

  2. Abdou HM. Remington: the science and practice of pharmacy. In: Gennaro AR, editors. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 654–66

  3. Löbenberg R, Krämer J, Shah MP, Amidon GL, Dressman JB. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res. 2000;17:439–44.

    Article  PubMed  Google Scholar 

  4. Shah VP, Konecny JJ, Everett RL, McCullough B, Noorizadeh AC, Skelly JP. In vitro dissolution profile of water-insoluble drug dosage forms in the presence of solubilizers. Pharm Res. 1989;6:612–8.

    Article  CAS  PubMed  Google Scholar 

  5. Yoshihara K, Gao Y, Shiga H, Wada R, Hisaoka M. Population pharmacokinetics of olmesartan following oral administration of it prodrug, olmesartan medoxomil in healthy volunteers and hypertensive patients. Clin Pharmacokinet. 2005;44:1324–9.

    Article  Google Scholar 

  6. Sagirli O, Onal A, Toker SE, Sensoy D. Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies. Chromatographia. 2007;66:213–8. doi:10.1365/s10337-007-0304-9.

    Article  CAS  Google Scholar 

  7. Koike H, Konse T, Sada T, Ikeda T, Hyogo A, Hinman D et al. Olmesartan medoxomil, a novel potent angiotensin II blocker. Annu Rep Sankyo Res Lab. 2003;55:1–91.

    CAS  Google Scholar 

  8. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20.

    Article  CAS  PubMed  Google Scholar 

  9. Bajerski L, Rossi RC, Dias CL, Fröehlich PE, Bergold AM. Stability-indicating LC determination of a new antihypertensive, olmesartan medoxomil in tablets. Chromatographia. 2008;68:991–6. doi:10.1365/s10337-008-0811-3.

    Article  CAS  Google Scholar 

  10. Pharmacopeial Forum. Pharmacopeial previews. 2004; 30:351–63.

    Google Scholar 

  11. Pharmacopeia US. USP 32 NF 27. Rockville: USP; 2009.

    Google Scholar 

  12. International Conference on Harmonisation (ICH). ICH harmonized tripartite guideline: validation of analytical procedure Q2A; 1994.

  13. International Conference on Harmonisation (ICH). ICH harmonized tripartite guideline: validation of analytical procedure Q2B; 1994.

  14. Rowe RC, Sheskey PJ, Welle PJ. Handbook of pharmaceutical excipients. In: Rowe RC, Sheskey PJ, Welle PJ, editors. Washington; 2000.

  15. Marques MRC, Brown W. Desenvolvimento e validação de métodos de dissolução para formas farmacêuticas sólidas orais. Analytica. 2002;1:48–51.

    Google Scholar 

  16. Costa PJC. Avaliação in vitro da lioequivalência de formulações farmacêuticas. Braz J Pharm Sci. 2002;38:141–53.

    Google Scholar 

  17. Ferraz HG, Consiglieri VO, Storpirtis S. Avaliação da cinética de dissolução de ampicilina em comprimidos comercializados no Brasil. Braz J Pharm Sci. 1998;34:93–109.

    CAS  Google Scholar 

  18. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–33.

    Article  CAS  PubMed  Google Scholar 

  19. Khan MZI. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. Int J Pharm. 1996;140:131–43.

    Article  CAS  Google Scholar 

  20. Brown CK, Chokshi HP, Nicherson B, Reed RA, Rohrs BR, Shah PA. Acceptable analytical practices of dissolution testing of poorly soluble compounds. Pharm Technol. 2004; 56–65.

  21. Rohrs BR. Dissolution method development for poorly soluble compounds. Dissol Technol. 2001;8:1–5.

    Google Scholar 

  22. Swanepoel E, Liebenberg W, Devarakonda B, Villiers MM. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie. 2003;58:117–21.

    CAS  PubMed  Google Scholar 

  23. Food and Drugs Administration (FDA). FDA guidance for industry: dissolution testing of immediate release solid oral dosage forms. Rockville: FDA; 1997.

    Google Scholar 

Download references

Acknowledgements

We acknowledge the Conselho Nacional de Pesquisa, Brazil for the financial support.

Author information

Authors and Affiliations

  1. Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Av. Ipiranga, 2752, CEP 90610-000, Porto Alegre, RS, Brazil

    Lisiane Bajerski, Rochele Cassanta Rossi, Carolina Lupi Dias, Ana Maria Bergold & Pedro Eduardo Fröehlich

Authors
  1. Lisiane Bajerski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rochele Cassanta Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carolina Lupi Dias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Maria Bergold
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pedro Eduardo Fröehlich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisiane Bajerski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bajerski, L., Rossi, R.C., Dias, C.L. et al. Development and Validation of a Discriminating In Vitro Dissolution Method for a Poorly Soluble Drug, Olmesartan Medoxomil: Comparison Between Commercial Tablets. AAPS PharmSciTech 11, 637–644 (2010). https://doi.org/10.1208/s12249-010-9421-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-010-9421-0

Key words

Search

Navigation